Antifungal Strategies for Patients with Hematologic Malignancies or Undergoing Stem-cell Transplant
A series of Live Grand Rounds Presentations and an On-demand Webcourse
Antifungal Strategies for Patients with Hematologic Malignancies or Undergoing Stem-cell Transplant.
A series of live CME/CE-certified in-hospital presentations will be held at locations nationwide in 2016 and an on-demand webcourse will be available in Summer 2016.
Patients with hematologic malignancies or receiving stem-cell transplant (SCT) have a higher susceptibility to invasive fungal infections.
Antifungal Strategies for Patients with Hematologic Malignancies or Undergoing Stem-cell Transplant will address the identification of high-risk patients, prophylaxis, and current evidence to support selection of antifungal therapy options.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
Discuss the clinical data for current, recently approved, and emerging antifungal agents
Evaluate the use of single and combination treatment strategies for fungal infections
Review individualized management of invasive fungal disease in patients with hematologic malignancies or hematopoietic stem-cell transplant recipients
This activity is intended for transplant physicians, transplant nurses, transplant NPs, transplant PAs, and transplant clinical coordinators, as well as infectious disease specialists and pharmacists.
Physicians - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
||Pharmacists - The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians - The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists - The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hours (0.10 CEUs) of continuing education credit (UAN number 0418-9999-16-003-L04-P).
This is an application-based activity.
Fee and Receiving CME/CE Credit
There is no fee for this educational activity. To receive CME/CE credit the participant must:
- Participate in this one-hour-long program in its entirety;
- Sign in on the sheet provided by the host coordinator;
- Complete the learning assessment and evaluation forms;
- Return the forms to the host coordinator.
Related Online Offerings
Click here to access the CME/CE-certified webcourse associated with this program.
Live Program Locations
If you are interested in attending a meeting in your local area, please contact Kathy Whyte at 443-909-7901 or email@example.com for the schedule.
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the grand rounds series, Antifungal Strategies for Patients with Hematologic Malignancies or Undergoing Stem-cell Transplant.
This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
- Risk-stratification of patients with hematologic malignancies
- Safety and efficacy of current and emerging antifungal therapies
- Antifungal prophylaxis and treatment
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
This version of the program slides has been CME/CE-certified and these slides are to be used for this activity. Download (PDF)
Steering Committee Biographies
All steering committee and speaking faculty disclosures will be provided onsite in program syllabi distributed to all grand rounds participants.
Elias Anaissie, MD
CTI Clinical Trial and Consulting Services
Associate, Metropolitan Infectious Diseases
Elias Anaissie, MD obtained his medical education from Saint Joseph University Medical School, Beirut, Lebanon (1972-1975) and the University of Paris XII, Creteil Faculty of Medicine, Paris, France (1976-1979). He completed a fellowship in hematology/oncology and in infectious diseases at the MD Anderson Cancer Center in Houston, TX, where he served on the faculty from 1987 to 1996. In 1996, he moved to the Myeloma Institute for Research and Therapy (MIRT) at the University of Arkansas for Medical Sciences (UAMS), where he was a Professor of Medicine, MIRT Deputy Chair, and Director of the Section of Cancer Supportive Care, positions he held for 16 years (1996-2012).
In June 2012, Dr. Anaissie joined the University of Cincinnati Cancer Institute (UCCI) to establish – along with 8 team members – the Section of Hematological Malignancies and Bone Marrow Transplantation (BMT), for which he served as Director. He also held the John and Gladys Strauss Endowed Chair in Cancer Research in 2014.
Because of his unique dual training and expertise in hematological cancers and infections in cancer and BMT patients, Dr. Anaissie focused his clinical and research activities on improving the outcomes of such patients, particularly those at risk for invasive fungal diseases. Dr. Anaissie’s research has resulted in 338 published articles in referenced journals, including a recent article on “How We Treat Invasive Fungal Disease in Patients with Acute Leukemia” in Blood. Dr. Anaissie is a member of the American Society of Clinical Oncology, American Society of Hematology, and Infectious Disease Society of America.
Joseph Bubalo, PharmD, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
Assistant Professor of Medicine
Oregon Health and Science University Hospital and Clinics
Joseph Bubalo, PharmD, BCPS, BCOP is an oncology pharmacotherapy specialist with Oregon Health and Science University and an Assistant Professor of Medicine with the Division of Hematology and Medical Oncology. Dr. Bubalo is board-certified in pharmacotherapy and oncology pharmacy. He has been active in the clinical care of oncology and hematopoietic stem-cell transplant (HSCT) patients for more than 20 years.
Dr. Bubalo has received research grants to investigate ways to improve the control of nausea and vomiting, as well as a variety of other topics in supportive care and infectious disease. He continues to look for ways to decrease the symptoms associated with antineoplastic and surgical therapies.